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Chemoradiation is now used more commonly for gastric cancer following publication of the US Intergroup trial results that
demonstrate an advantage to adjuvant postoperative chemoradiotherapy. However, there remain concerns regarding the toxicity of
this treatment, the optimal chemotherapy regimen and the optimal method of radiotherapy delivery. In this prospective study, we
evaluated the toxicity and feasibility of an alternative chemoradiation regimen to that used in the Intergroup trial. A total of 26
patients with adenocarcinoma of the stomach were treated with 3D-conformal radiation therapy to a dose of 45Gy in 25 fractions
with concurrent continuous infusional 5-fluorouracil (5-FU). The majority of patients received epirubicin, cisplatin and 5-FU (ECF) as
the systemic component given before and after concurrent chemoradiation. The overall rates of observed grade 3 and 4 toxicities
were 38 and 15%, respectively. GIT grade 3 toxicity was observed in 19% of patients, while haematologic grade 3 and 4 toxicities
were observed in 23%. Our results suggest that this adjuvant regimen can be delivered safely and with acceptable toxicity. This
regimen forms the basis of several new studies being developed for postoperative adjuvant therapy of gastric cancer.
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Carcinoma of the stomach remains a major cause of cancer-related
death in most Western countries. Surgery is the only proven
effective therapy, but overall 5-year survival rates remain low after
resection. Patterns of failure data from Western series document
that approximately 60% of those with positive lymph nodes or
extension of the primary tumor through the serosa fail locor-
egionally (Gunderson and Sosin, 1982; Landry et al, 1990). The
recently reported Gastric Surgical Adjuvant Trial (INT0116) has
established combined chemoradiotherapy as an integral compo-
nent of standard adjuvant therapy for high-risk, completely
resected adenocarcinoma of the stomach (Macdonald et al,
2001). There was a major survival advantage to the use of
combined modality therapy postoperatively, with 3-year survival
improving from 41 to 50%. These data support the undertaking of
further studies to build on the results of the Intergroup study, as
there remain several concerns among both medical and radiation
oncologists regarding implementation of this treatment.
The first relates to the toxicity associated with the treatment.
The combined modality regimen in this programme was associated
with considerable toxicity, with grade 3 and 4 toxicities occurring
in 41 and 32% of cases, respectively (Macdonald et al, 2001).
The second area of concern relates to the optimal chemotherapy
regimen. The Intergroup study employed bolus 5-fluorouracil (5-
FU) and leucovorin delivered before, during and after radiation.
This regimen was chosen because it represented the standard of
care at the time the trial was developed in the early 1990s.
However, many medical oncologists feel that this regimen is now
outdated and that there are more active regimens available for
gastric cancer. The failure pattern data from INT0116 suggest a
minimal effect of 5-FU/leucovorin on regional and distant failure
(Macdonald et al, 2001). The high recurrence rate, even in the
chemoradiation arm, clearly indicates the need for improved
systemic therapies.
The last area of concern relates to the radiotherapy planning and
treatment techniques employed in INT0116. Radiotherapy fields
were designed using conventional simulation with minimal use of
CT planning to define the clinical target volume, and all patients
were treated with simple parallel-opposed anterior and posterior
field arrangements (Smalley et al, 2002). However, many radiation
oncologists are reluctant to treat such large abdominal volumes
with anterior and posterior fields due to concerns about normal
tissue toxicity, particularly in relation to the kidneys and spinal
cord. Recent computer-planning developments in radiotherapy
techniques offer major advantages over the traditional opposed-
field approaches devised in the 1960s, with the potential to reduce
normal tissue toxicity (Dobelbower et al, 1980; Chu et al, 1992).
Following the initial reporting of INT0116 results (ASCO 2000),
we began treating patients using an alternative regimen of
chemoradiation for gastric cancer, employing a more current
chemotherapy combination of epirubicin, cisplatin and 5-fluor-
ouracil (ECF), given before and after concurrent chemoradiation.
The chemoradiation component combined modern conformal
radiotherapy techniques with continuous infusional 5-FU at a Received 16 June 2003; revised 31 July 2003; accepted 8 August 2003
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lstandard dose of 225mgm
 2day
 1. As this regimen represents
current standard practice at our institution, informed consent and
Ethics Committee approval were not required. Patient and
treatment data were collected prospectively as part of a pilot
study to evaluate the toxicity and feasibility of this regimen.
MATERIALS AND METHODS
Patients
The study population consisted of two groups of patients: (1)
Those with histologically confirmed adenocarcinoma of the
stomach or gastro-oesophageal junction, who had undergone a
complete R0 resection with negative margins. Patients in this
group were eligible for postoperative adjuvant therapy if they had:
tumour stage T3–4 and/or N1–2; performance status of 2 or lower
according to the criteria of the Eastern Cooperative Oncology
Group (ECOG) and adequate oral nutrition (caloric intake of
1500cal per day). (2) Those with locally advanced, histologically
confirmed adenocarcinoma of the stomach or gastro-oesophageal
junction not considered suitable for surgical resection based on
clinical evaluation of tumour size, invasion of adjacent structures
and advanced locoregional node involvement. Two patients who
were considered unsuitable for surgery based on medical
comorbidity were also eligible. Patients in this group were eligible
for definitive chemoradiation if they had: no evidence of distant
metastases; ECOG performance status 2 or lower and adequate
nutritional status. Several patients who achieved a good response
to chemoradiation underwent subsequent surgical resection.
Treatment
The chemoradiation regimen was the same for both patient
groups. The majority of patients received one cycle of ECF
chemotherapy (epirubicin 50mgm
 2 IV day 1, cisplatin 60mgm
 2
IV day 1 and 5-FU 200mgm
 2day
 1 IV 21-day continuous
infusion) initiated on day 1, and this was followed by chemor-
adiotherapy beginning 28 days after the start of the initial cycle of
chemotherapy. Chemoradiotherapy consisted of 45Gy of radiation
at 1.8Gy per day, 5 days per week for 5 weeks, with concurrent
continuous infusion 5-FU (225mgm
 2day
 1, 7 days per week,
throughout the entire period of radiotherapy). Continuous
infusion 5-FU was delivered by ambulatory pump via a central
venous access device with 1mg warfarin prophylaxis. All patients
received 5HT3 antagonists on day 1 of ECF and continued for 2
days after. At 1 month after the completion of radiotherapy, two
further cycles of ECF chemotherapy were given. A small number of
patients received alternative fluorouracil-based regimens before
and after radiation, most commonly fluorouracil and leucovorin
(fluorouracil 425mgm
 2day
 1 and leucovorin 20mgm
 2day
 1
for 5 days), as delivered in INT0116.
Radiotherapy generally followed the recommendations outlined
in INT0116 (Macdonald et al, 2001). The 45Gy of radiation was
delivered in 25 fractions, five days per week, to the tumour bed,
anastomoses and stumps, and regional lymphatics. The design of
the radiation treatment fields for postoperative treatment was
individualised depending upon the extent and location of the
primary tumour and involved lymph nodes, and the type of
surgery performed. For definitive chemoradiation, the radiation
treatment fields were the same as for postoperative treatment,
except that there are no anastomoses that need to be covered.
Lymph node stations included in the radiation fields included
perigastric, coeliac, splenic hilar, suprapancreatic, porta hepatis,
pancreaticoduodenal and local para-aortic nodes. In patients with
tumours confined to the proximal one-third of the stomach or
gastro-oesophageal junction with limited lymphatic invasion,
treatment of the pancreaticoduodenal nodes was omitted. Simi-
larly, treatment of the splenic hilar nodes was omitted in patients
with tumours of the lower third of the stomach or antrum. The
clinical target volume (CTV) was defined in all patients using CT
planning, and all were treated using a standardised 3D conformal
technique that consisted of a ‘split-field’, monoisocentric arrange-
ment employing six radiation fields. Radiation was delivered using
6–18MV photons. Dose–volume histograms (DVHs) were re-
corded for the kidneys, liver and spinal cord in all patients.
Baseline renal scans were performed to assess differential renal
function and glomerular filtration rate (GFR) prior to commencing
radiotherapy.
Patient follow-up
All patients were reviewed weekly during treatment, and two
weekly post-treatment for 6 weeks with physical examination,
toxicity assessment and full blood count and biochemistry. Acute
toxicities were graded using the NCI common toxicity criteria. Late
effects were graded according to RTOG/EORTC late effects criteria.
For the purposes of comparison with the Intergroup study, acute
toxicities have been presented using the criteria of the Southwest
Oncology Group (SWOG). Follow-up of both groups occurred at 3-
month intervals for 2 years, then at 6-month intervals for 3 years,
and yearly thereafter. The follow-up consisted of physical
examination, full blood count and biochemistry. CT and PET
scanning was only performed if clinically indicated. Patients
receiving definitive chemoradiation usually underwent repeat
gastroscopy to assess the response. The site and date of the first
relapse and the date of death, if the patient died, were recorded.
RESULTS
Patient characteristics
Between July 2000 and May 2002, 26 patients were treated (Table 1).
The majority received postoperative adjuvant treatment following
complete surgical resection. One patient underwent a formal D2
lymph node dissection, six patients underwent D1 nodal dissec-
tions and 11 patients underwent less than D1 nodal dissections.
The 18 patients who underwent initial surgical resection were
staged according to 2002 UICC criteria: Stage II-2, Stage IIIA-10,
Stage IIIB-4 and Stage IV-2. The majority had T3 tumours and all
had involved lymph nodes. Of the eight patients who were treated
with definitive chemoradiation, three underwent subsequent
surgical resection. The location of the primary tumour within
the stomach showed a slight predominance of cardiac and gastro-
oesophageal junction tumours.
There was some variation in the chemotherapy regimens
delivered (Table 1). Since the chemotherapy that was delivered
concurrently with radiation was usually administered by medical
oncologists from our institution, over 90% of the patients received
continuous infusional 5-FU with radiotherapy. Two patients
received fluorouracil/leucovorin during radiation, as given in
INT0116. However, the chemotherapy that was delivered before
and after radiation was, in some patients, administered by medical
oncologists from outside institutions, some of whom did not use
ECF chemotherapy. Overall, approximately 70% of patients
received ECF, while the remainder received alternative fluorour-
acil-based regimens, usually fluorouracil/leucovorin. All treat-
ments received by all 26 patients are summarised in Figure 1.
Treatment toxicity
Of the 26 patients who commenced chemoradiation, 21 (81%)
completed treatment as planned. One patient receiving definitive
chemoradiation failed to complete his continuous infusional 5-FU
during radiotherapy. This patient developed a pulmonary embolus
in week 5 of radiotherapy and his chemotherapy was ceased. The
ECF before and after chemoradiation for gastric cancer
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llast two cycles of ECF were not given. Two further patients
receiving definitive chemoradiation failed to complete their
postchemoradiation ECF chemotherapy: one underwent surgery
following a good partial response to one cycle of ECF and
combined chemoradiation, and the other was not given the last two
cycles of ECF due to grade 3 nausea and mucositis. One patient
receiving postoperative treatment refused the last cycle of ECF
chemotherapy because of persistent nausea. Another postoperative
patient (receiving the INT0116 regimen) required a radiotherapy
treatment break (of 1 week) for nausea and vomiting. All other
patients completed their radiotherapy as planned, without treat-
ment breaks.
The major acute toxic effects attributable to the adjuvant
regimen (both combined chemoradiation and chemotherapy
without radiation) were defined as those of grade 3 or higher,
and are summarised in Table 2. The overall rate of grade 3 toxicity
was 38%. Grade 4 toxicity occurred in only four patients (15%);
two developed neutropenia without sepsis, one developed severe
fatigue requiring hospitalisation, and one developed a pulmonary
embolus which was not necessarily treatment related. For those
patients who received ECF chemotherapy, the rates of grade 3 and
4 toxicities were 41 and 24%, respectively. The most commonly
reported toxic effects were gastrointestinal (GIT) and haematolo-
gic. The overall rate of grade 3 GIT toxicity was 19%, with no
patients experiencing grade 4 GIT toxic effects. Gastrointestinal
toxicity consisted mainly of nausea that occurred predominantly
during concurrent chemoradiation. Haematologic grade 3 and 4
toxicities were reported in 23% of patients and consisted mainly of
leukopenia occurring during chemotherapy without radiation. For
patients receiving ECF chemotherapy, the corresponding rates of
grade 3 GIT and grade 3/4 haematologic toxicities were 18 and
29%, respectively. The toxicity rates for patients receiving
definitive chemoradiation vs postoperative chemoradiation are
also shown in Table 2, as well as those for postoperative patients
who were treated with ECF chemotherapy. There were no
treatment-related deaths.
Late radiation toxicity has been observed in only one patient
who developed RTOG grade 3 enteritis. At 4 months after
completing chemoradiation, this patient developed persistent
melena that necessitated repeated blood transfusions. Gastroscopy
and enteroscopy revealed inflammatory changes affecting the
mucosa of the duodenum and proximal jejunum. Laparoscopy
demonstrated oedema of the duodenum and proximal jejunum,
but normal-appearing small bowel elsewhere. Abnormalities were
also noted on CT, which showed thickening of the small bowel wall
involving the duodenum. The distribution of these small bowel
abnormalities was found to correspond to radiation fields that
were employed to treat the infrapyloric and pancreaticoduodenal
lymph nodes. The patient’s symptoms resolved after approxi-
mately 3 months, without any specific treatment.
Disease relapse
The median follow-up period for all 26 patients is 12 months. The
site of first relapse was recorded for the 18 patients who were
treated postoperatively. Of these 18 patients, 11 were treated with
ECF chemotherapy and seven were treated with alternative
fluorouracil-based regimens. Two of the 11 patients who received
ECF developed recurrence: one with peritoneal carcinomatosis,
and one with both peritoneal carcinomatosis and liver metastases.
Both patients have died following recurrence. Three of the seven
patients who received non-ECF chemotherapy developed recur-
rence: one with locoregional disease, one with liver metastases and
one with peritoneal carcinomatosis, who subsequently died
following recurrence. Using Kaplan–Meier estimates, the 1-year
relapse-free survival for all 18 postoperative patients is 82%
(standard error 9%) (Figure 2a). Estimated 1-year relapse-free
survival for the ECF group is 87% (standard error 11%), and for
the group that did not receive ECF it is 71% (standard error 17%)
(Figure 2b).
Three patients who were treated with definitive chemoradiation
for initially unresectable disease subsequently underwent surgery
following a favourable response to treatment. One patient with a
locally advanced tumour of the cardia and extensive regional
lymphadenopathy obtained a complete response both at the
primary site and involved lymph nodes, as assessed endoscopically
(with biopsy) and on follow-up PET scan. He underwent complete
Table 1 Patient characteristics
Characteristic
No. of patients 26
Age (years)
Median 60
Range 34–82
Sex
Male 21
Female 5
Treatment
Postoperative 18
Definitive 8
Nodal dissection
D2 1
D1 6
oD1 11
T stage (postoperative patients)
T2 4
T3 13
T4 1
Location of primary tumour
G–O junction/cardia 10
Body 9
Antrum 7
Chemotherapy
ECF 17
CI 5-FU during RT 24
G–O, gastro-oesophageal; CI, continuous infusional; RT, radiotherapy.
Patients with gastric cancer
 n=26 
Surgery and postoperative
chemoradiation
  n=18 
Neoadjuvant/definitive
chemoradiation
  n=8 
 ECF 
chemotherapy 
 n=11 
Alternative
5-FU-based
chemotherapy
 n=7 
ECF 
chemotherapy
 n=6 
Alternative
5-FU based
chemotherapy
 n=2 
Surgery following
chemoradiation
 n=3  
Surgery following
chemoradiation
 n=0  
Figure 1 Flow diagram showing treatment delivered.
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lsurgical resection, but unfortunately developed cerebral metastases
9 months after completion of chemoradiation. The remaining two
patients obtained a partial response following chemoradiation and
remained alive and disease free 10 and 21 months after complete
surgical resection.
DISCUSSION
Worldwide, large amounts of resources have been expended in the
search for an effective adjuvant therapy to reduce the risk of
postoperative relapse following surgery for gastric cancer. Post-
operative adjuvant chemotherapy for gastric cancer has been
thoroughly explored over the past 10–15 years. Several recent
meta-analyses have indicated that, even with pooled data,
postoperative adjuvant systemic therapy produces only a modest
improvement in survival (Earle and Maroun, 1999; Mari et al,
2000; Janunger et al, 2001). Likewise, adjuvant radiotherapy alone
has also failed to demonstrate any survival benefit (Hallissey et al,
1994). Recognition of the high locoregional failure rates following
surgery has resulted in four separate randomised trials evaluating
the role of extended lymph node dissection (Robertson et al, 1994;
Dent et al, 1988; Bonenkamp et al, 1999; Cuschieri et al, 1999). All
the four trials demonstrate a substantial increase in morbidity and,
in some series, operative mortality with extended lymph node
dissection. None show improvement in overall survival.
The results of the US Intergroup trial, which demonstrate a
survival advantage to the use of adjuvant chemoradiotherapy, have
changed the standard of care in some parts of the world for the use
of both chemotherapy and radiotherapy in the postoperative
setting for patients with high-risk disease. Implementation of this
treatment has, however, posed several problems with respect to
both chemotherapy and radiotherapy. At the same time, it has also
provided new opportunities to build on the Intergroup results by
trying to improve treatment efficacy and reduce treatment toxicity.
The chemotherapy regimen used in INT0116 was associated with
considerable toxicity and some medical oncologists are reluctant
to use this regimen given that more active and apparently less toxic
combinations are now available. The Intergroup study was
initiated over 10 years ago and the chemotherapy that was used
was not optimised, but it was adopted since this was a regimen that
had been through toxicity studies. An analysis of failure patterns
indicates that the improvement noted in INT0116 was entirely due
to an improvement in local control with no effect on distant
metastases (Macdonald et al, 2001). This strongly suggests that the
5-FU/leucovorin combination, as delivered in this study, is
producing its effect through radiosensitisation to assist radiation
therapy in obtaining local control.
In our study, the majority of patients received ECF both before
and after chemoradiation. This regimen was first reported in 1991,
with the three drugs being selected on the basis of their single
agent activity in upper GIT tumours (Beer et al, 1983; Cersosimo
and Hong, 1986; Machover et al, 1986), and on the synergy
demonstrated between 5-FU and cisplatin in preclinical models
(Etienne et al, 1991). ECF is associated with response rates of
approximately 45% in patients with metastatic gastric cancer,
although higher response rates are seen when used for locally
advanced disease (Findlay et al, 1994; Waters et al, 1999). We also
employed continuous infusional 5-FU delivered concurrently with
radiation. Continuous, as opposed to bolus, 5-FU during radiation
for other GIT tumours is less toxic and better tolerated, and is
proposed to maximise the opportunities for radiosensitisation (O-
Connell et al, 1994; Poen et al, 1998).
The toxicity rates observed in this study compare favourably to
those reported in INT0116. The overall rates of grade 3 and 4 acute
toxicity for our patients were 38 and 15%, respectively. For those
patients receiving ECF, the corresponding rates were 41 and 24%.
However, this group includes some patients treated with definitive
chemoradiation, who, in general, were less medically fit and had
more advanced tumours requiring larger radiation fields. If we
exclude these patients, then the rates of grade 3 and 4 toxicities for
postoperative patients receiving ECF were 27 and 18%. As
described above, GIT and haematologic toxic effects predomi-
nated. For the patient groups listed in Table 2, the rates of grade 3
GIT toxicity range from 9 to 25%, while the rates of grade 3/4
haematologic toxicity range from 22 to 29% for the different
subgroups. The lower rates of haematologic and overall grade 4
toxicity compared to those reported in INT0116 (54 and 32%,
respectively) may reflect the chemotherapy regimen employed,
particularly the use of continuous infusional 5-FU, which is known
to produce less myelotoxicity compared to bolus 5-FU. Although a
number of patients in this study did not receive ECF, the majority
(90%) did receive continuous infusional 5-FU during radiation.
A further contributing factor to the favourable toxicity profile,
particularly GIT toxicity, may be the use of more conformal
radiotherapy techniques compared to the simple anterior and
posterior fields used in INT0116. All of our patients were able to
complete their radiotherapy as planned, whereas 17% of patients
in the Intergroup study did not complete their radiotherapy due to
toxic effects. The volume of the small bowel that is included in the
radiation fields is reduced by using multiple fields that conform to
the high-risk target volume. Very few of our patients experienced
any significant vomiting or diarrhoea and the most common acute
GIT toxic effect was nausea. A major concern among radiation
oncologists is the potential for late toxicity associated with high-
dose radiation to the abdomen. By using CT-assisted computer
planning and 3D conformal radiation techniques, we have been
able to reduce the dose to critical normal structures such as
kidneys, spinal cord and small bowel. Comparative dose–volume
histograms comparing our multiple-field technique with an
Table 2 Acute toxicity
All patients (n¼26)
All patients
receiving ECF
(n¼17)
All postoperative
patients
(n¼18)
All definitively
treated patients
(n¼8)
Postoperative patients
receiving ECF
(n¼11)
% (no.)
Overall grade 3 38 (10) 41 (7) 28 (5) 63 (5) 27 (3)
Overall grade 4 15 (4) 24 (4) 11 (2) 25 (2) 18 (2)
GIT grade 3 19 (5) 18 (3) 17 (3) 25 (2) 9 (1)
Haematologic grade 3 and 4 23 (6) 29 (5) 22 (4) 25 (2) 27 (3)
Major toxic effects were defined as those of grade 3 or higher. Toxic effects have been presented according to SWOG criteria. Data are presented for: all patients who received
chemoradiotherapy; patients who received ECF; patients treated postoperatively; patients treated with definitive chemoradiation; and postoperative patients who received ECF.
ECF¼epirubicin, cisplatin and 5-fluorouracil; GIT¼gastrointestinal.
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lanterior/posterior technique demonstrate considerable sparing of
these critical structures from the high-dose volume (data not
shown).
The short median follow-up precludes any meaningful analysis
of relapse and survival patterns. However, our 1-year relapse-free
survival rate for postoperative patients compares favourably to
that observed for patients in the adjuvant chemoradiation arm of
the Intergroup study. Longer follow-up and increased patient
numbers are required to compare the outcomes of patients
receiving ECF chemotherapy with those receiving alternative
fluorouracil-based regimens.
The Intergroup study is often criticised because of the
inadequacy of the nodal dissections performed with 54% of
patients undergoing less than a D1 lymph node dissection. It has
been claimed that the benefits of chemoradiation are only due to
the compensation of poor surgery, and that these benefits would
not be seen if a D1 or D2 dissection had been performed. However,
this is a hypothesis that remains to be proven. To date, the
published randomised trials have not shown that more extensive
nodal dissections are associated with improved survival. We,
therefore, do not have definitive data indicating that, in a multi-
institutional study, D2 operations are superior. It is possible that
better surgery using a formal D1 or D2 dissection may decrease the
need for radiation. On the other hand, it is also possible that when
better surgery is combined with chemoradiation, there may be a
further improvement in local control as seen in the Intergroup
study. The role of radiotherapy in preventing locoregional
recurrence for patients who have undergone at least a D1
dissection would therefore be an appropriate question for a future
clinical trial.
The preliminary report of the MRC MAGIC trial (ASCO 2003)
also supports the use of ECF chemotherapy in the adjuvant and
neoadjuvant setting. This trial has shown that perioperative ECF
improves progression-free survival in patients with operable
gastric cancer. While the survival benefit seen in the US Intergroup
trial was mainly due to improved local control from radiotherapy
(with no effect on distant metastases), the benefit observed in the
MAGIC study was due mainly to a reduction in distant metastases.
It would therefore seem logical to combine optimal local treatment
with optimal systemic treatment, as we have done in this study.
The emergence of combined chemoradiotherapy as an effective
adjuvant treatment with significant benefit provides new oppor-
tunities to develop improved treatment by combining more
effective systemic therapies with modern conformal techniques
of radiation delivery. Our results suggest that an adjuvant regimen
employing ECF as the systemic component before and after
concurrent chemoradiation with continuous infusional 5-FU can
be delivered safely and with acceptable toxicity. This study forms
the basis of a new Australasian multicenter trial conducted under
the auspices of the Trans-Tasman Radiation Oncology Group
(TROG) that will evaluate the feasibility of this regimen on a
national scale, and attempt to standardise radiation oncology
techniques among centres that have different practices and
equipment. An important aspect of this study is the radiation
oncology quality control review procedure that will involve ‘real
time’ central review of all radiotherapy treatment plans prior to
patients commencing treatment. A detailed set of radiotherapy
guidelines has been developed to ensure the accuracy and
consistency of radiotherapy planning.
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